LACTOLOGY FOUNDATION

Gefarnate (ATC A02BX07) is a gastroprotective, anti-ulcer agent with very limited published data on breastfeeding, but based on its physicochemical profile, clinical use, and lack of reported toxicity, it can be considered compatible with lactation, with negligible expected risk to the breastfed infant.file+1

Active substance and ATC classification

• ATC class: A02BX07 – other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD), subgroup of “other” anti-ulcer/gastroprotective drugs.precision.fda+1
• Active ingredient: Gefarnate, a water-insoluble terpene fatty acid ester with gastroprotective properties.drugcentral+1
• Chemical nature: organic small molecule, classified as an anti-ulcer/gastroprotective agent that supports mucosal healing.pubchem.ncbi.nlm.nih+1

Mechanism of action and indications

Gefarnate facilitates the healing and optimizes the function of mucosal tissue in the gastrointestinal tract. It enhances the mucosal barrier by stimulating mucus production and supporting mucosal defense against gastric acid and other irritants.pubmed.ncbi.nlm.nih+4

Main therapeutic uses include:

• Treatment and prevention of gastric and duodenal ulcers, and gastritis.drugbank+3
• Management of peptic ulcer disease and upper gastrointestinal mucosal lesions, including erosive gastritis and dyspeptic complaints.synapse.patsnap+3
• Investigational or off-label uses include certain cardio‑cerebrovascular conditions (as a lipid-lowering or vasoprotective adjunct) and ocular use (dry eye), where increased mucin production in conjunctiva and cornea has been observed experimentally.medchemexpress+3

Typical adult oral doses in clinical practice are around 300 mg per day, usually divided, although specific licensed posology may vary by country and product.mims+1

General toxicity and safety profile

Gefarnate is generally characterized by a wide therapeutic margin in experimental studies. Reported median lethal dose (LD50) values in animals are high (on the order of several g/kg), supporting low acute toxicity relative to therapeutic doses; one source cites an LD50 around 9 g/kg.file+1

Animal models show that gefarnate, at doses substantially above human therapeutic exposure, reduces progression of acute gastric mucosal lesions by decreasing mucus depletion, neutrophil infiltration, and oxidative stress, without notable systemic toxicity signals. Clinical information sources describe it simply as a gastroprotective/anti-ulcer agent with no specific pattern of serious adverse reactions in routine use.pubmed.ncbi.nlm.nih+2

Commonly available references do not highlight significant organ toxicity, carcinogenicity, or reproductive toxicity, and no specific safety signals in humans have been consistently reported. Overall, the toxicological profile in adults appears benign when used at standard doses.drugbank+2

Pregnancy risk assessment

Some local lactology/toxicology references classify gefarnate as FDA pregnancy category A, implying controlled data in pregnant women have not demonstrated fetal risk in the first trimester and there is no evidence of risk in later trimesters. This categorization is based on long-term clinical experience and the lack of published teratogenic or embryotoxic signals.file+1

Nonetheless, global labeling may be heterogeneous and many modern regulatory frameworks have moved away from letter categories toward narrative risk summaries; therefore, individual product information should still be consulted.mayoclinic

Lactation pharmacokinetics and infant exposure

Direct human lactation pharmacokinetic data for gefarnate are not available in the standard literature. However, several characteristics allow a reasoned extrapolation:drugcentral+2

• Molecular weight is in the low-to-mid hundreds of daltons (≈400 Da range), which is compatible with some passage into breast milk.pubchem.ncbi.nlm.nih+1
• Gefarnate is a lipophilic terpene fatty acid ester and is practically water-insoluble, suggesting preferential partitioning into lipid compartments and potentially slightly higher milk than plasma concentrations on a ratio basis.drugcentral+2
• Systemic bioavailability after oral dosing appears limited, with scarce data on absorption and protein binding; several sources emphasize lack of detailed pharmacokinetic information.drugbank+2

Based solely on molecular weight and lipophilicity, passage into milk would be expected but at low absolute quantities, given the modest maternal plasma levels at therapeutic dosing and the relatively low doses used clinically (≈300 mg/day). From a toxicological perspective, the large safety margin between therapeutic doses and experimental LD50 values implies that even if a small fraction reaches the infant via milk, exposure will remain far below toxic thresholds.pubmed.ncbi.nlm.nih+3

No published case reports were identified describing adverse effects in breastfed infants attributable to gefarnate. In the absence of such reports, and given its pharmacological profile and long-standing clinical use, some expert lactology sources classify gefarnate as fully compatible with breastfeeding (toxico‑lactation category I – “safe during lactation”).mayoclinic+3

Lactation risk assessment and practical recommendations

Overall lactation risk:

• On current evidence, gefarnate can be regarded as compatible with breastfeeding, with minimal expected risk to the breastfed infant when used in standard oral doses.mayoclinic+3
• Theoretical considerations (low water solubility, relatively high LD50, absence of infant case reports) support this favorable profile.file+2

Clinical precautions in breastfeeding women:

• Use the lowest effective dose for the shortest necessary duration, particularly in mothers of premature or medically fragile infants, who are more sensitive to any drug exposure via milk.mayoclinic
• Monitor the infant for nonspecific signs such as changes in feeding, unusual somnolence or irritability, vomiting, or poor weight gain, although such effects are not expected based on the drug’s profile.mayoclinic
• In the presence of severe maternal gastrointestinal disease requiring polypharmacy, consider the cumulative exposure from co‑medications and prioritize agents with well-described lactation safety profiles where feasible.sps+1

In the context of the broader group of drugs for acid-related disorders, many first-line alternatives (for example, omeprazole or famotidine) are considered compatible with breastfeeding and have more robust lactation data, but gefarnate does not present specific reasons for avoidance where it is clinically indicated.sps+1